These macrophages could hold the key to even more targeted cancer treatments.

Pollard, the ACS acknowledged Joseph Fraumeni, M.D., M.Sc., for Malignancy Control, and Patricia Ganz, M.D., for Clinical Study. This is actually the second ACS Medal of Honor awarded to a researcher at the Albert Einstein Cancer Center. Susan Band Horwitz, Ph.D., received the Medal of Honor in 2008 for Clinical Research.. Albert Einstein researcher receives Medal of Honor from American Tumor Society Albert Einstein College of Medication of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Tumor Society in recognition of his research into the critical part the tumor microenvironment plays in modulating cancers behavior, specifically the role that people of the innate immune cells known as macrophages play both in normal development and in promoting tumor progression.This hurdle is compounded by the complexity of the dengue virus. Despite the fact that there are only four different serotypes, the fairly high rates of mutation continuously means the virus evolve, and this contributes to the fantastic diversity of the dengue infections circulating globally. Furthermore, in some full cases, the immune response created following infection by among the four dengue viruses appears to increase the risk of serious dengue when the same specific is infected with the remaining three infections. With nearly half the world's population vulnerable to dengue infection and an estimated 400 million people obtaining infected each full year, the necessity for a long-lasting and safe vaccine hasn’t been greater.